Parkside Investments’s Amgen AMGN Stock Holding History

Parkside Investments’s Portfolio AMGN Stock Details AMGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-98	Closed	-$23K	–	89
2022 Q1	$23K	Buy	+98	New	+$22.5K	﹤0.01%	127
2018 Q4	–	Sell	-10	Closed	-$2K	–	106
2018 Q3	$2K	Buy	+10	New	+$1.97K	﹤0.01%	149

Other funds holding AMGN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Parkside Investments's AMGN Position: Q2 2022 in Review

Parkside Investments sold out of Amgen (AMGN) in Q2 2022, closing a stake of 98 shares — an estimated $23K sold.

Parkside Investments first reported a position in AMGN in Q3 2018 and held it in 2 quarters. The position peaked at $23K in Q1 2022. 2,353 funds tracked by Wall St. Rank hold AMGN as of Q2 2022.

Parkside Investments reported no remaining Amgen position as of Q2 2022 after selling out during the quarter.
Parkside Investments sold 98 Amgen shares in Q2 2022, an estimated $23K.
Parkside Investments first reported a position in Amgen in Q3 2018 and held it in 2 quarters.
Parkside Investments's Amgen position peaked at $23K in Q1 2022.
2,353 funds tracked by Wall St. Rank held Amgen as of Q2 2022.

Based on Parkside Investments's 13F filing for Q2 2022, filed 13 Jul 2022.